pravastatin has been researched along with Obesity in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ávila-González, AE; García-Cobian, TA; García-Iglesias, T; Pérez-Guerrero, EE; Raffoul-Orozco, AK; Rodríguez-Razón, CM; Rubio-Arellano, ED | 1 |
| Beck, B; Donner, D; du Toit, EF; Headrick, JP; Oi, M; Peart, J; Wendt, L | 1 |
| Hur, J; Kang, JY; Kim, YK; Lee, SY; Liang, L; Rhee, CK | 1 |
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Barron, FE; Burridge, PW; Churko, JM; Diecke, S; Gold, JD; Gu, M; He, C; Hu, S; Kooreman, NG; Lee, J; Mordwinkin, NM; Ong, SG; Wu, H; Wu, JC | 1 |
| Cosentino, F; Costantino, S; Paneni, F | 1 |
| Araki, K; Kakuma, T; Katsuragi, I; Masaki, T; Yoshimatsu, H | 1 |
| Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Tajima, N; Teramoto, T; Uchiyama, S | 1 |
| Anazawa, T; Furuya, S; Hirayama, A; Iida, K; Kawamata, H; Kumabe, N; Matsumoto, M; Nagao, K; Takahashi, H; Tani, S; Washio, T | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Wilke, RA | 1 |
| Cobbe, S; Ford, I; Logue, J; Macfarlane, P; Murray, HM; Packard, C; Sattar, N; Shepherd, J; Welsh, P | 1 |
| Schück, O; Stollová, M; Teplan, V; Vítko, S | 1 |
| Cobbe, SM; Ford, I; Gaw, A; Haffner, SM; Isles, C; Macfarlane, PW; O'Reilly, DS; Packard, CJ; Sattar, N; Scherbakova, O; Shepherd, J | 1 |
| Matsui, T; Sato, T; Takeuchi, M; Yamagishi, S | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Magi, L; Morosini, P; Rafaiani, S; Settembri, P; Sforza, P | 1 |
| Abe, M; Caslake, MJ; Fukuhara, A; Funahashi, T; Kihara, S; Kobayashi, H; Komuro, R; Matsuda, M; McMahon, A; Shepherd, J; Shimomura, I; Takagi, T | 1 |
| Abe, M; Fukuhara, A; Kobayashi, H; Komuro, R; Matsuda, M; Miyata, Y; Nakayama, Y; Shimomura, I | 1 |
| Boni, M; De Sio, G; Mazzanti, L; Monteburini, T; Polenta, M; Testa, I | 1 |
| Barrett e Pesquisadores, AC | 1 |
| Albarrán, OG; García-Robles, R; Rábano, A; Ruilope, LM; Villa, E | 1 |
2 review(s) available for pravastatin and Obesity
| Article | Year |
|---|---|
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
4 trial(s) available for pravastatin and Obesity
| Article | Year |
|---|---|
Association of body mass index with coronary plaque regression: 6-month prospective study.
Topics: Aged; Body Mass Index; Cholesterol; Cholesterol, HDL; Coronary Artery Disease; Female; Humans; Leukocyte Count; Male; Middle Aged; Obesity; Pravastatin; Prospective Studies; Treatment Outcome; Ultrasonography | 2009 |
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation.
Topics: Body Mass Index; Coronary Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Obesity; Poverty; Pravastatin; Risk Factors; Scotland | 2011 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
[Pravastatin multicenter clinical trial in patients with hypercholesterolemia and multiple risk factors].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Diabetes Complications; Female; Humans; Hypercholesterolemia; Hypertension; Male; Menopause; Middle Aged; Obesity; Pravastatin; Risk Factors; Sex Factors; Smoking | 1997 |
16 other study(ies) available for pravastatin and Obesity
| Article | Year |
|---|---|
Combination effect naringin and pravastatin in lipid profile and glucose in obese rats.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Drug Therapy, Combination; Flavanones; Glucose; Lipid Metabolism; Lipids; Male; Obesity; Pravastatin; Rats; Rats, Wistar; Triglycerides | 2018 |
Pravastatin improves risk factors but not ischaemic tolerance in obese rats.
Topics: Animals; Blood Glucose; Body Weight; Diet, Carbohydrate Loading; Diet, High-Fat; Disease Models, Animal; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Lipid Peroxidation; Male; Mitochondria; Mitochondrial Dynamics; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Obesity; Pravastatin; Rats; Rats, Wistar; Risk Factors | 2018 |
Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model.
Topics: Adiponectin; Adipose Tissue; Animals; Anti-Asthmatic Agents; Antibodies; Asthma; Bronchoconstriction; Diet, High-Fat; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-17; Leptin; Lung; Mice, Inbred C57BL; Obesity; Pravastatin; Th17 Cells; Th2 Cells | 2018 |
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism.
Topics: Analysis of Variance; Animals; Apoptosis; Cell Differentiation; Diet, High-Fat; Endothelial Cells; Enzyme Inhibitors; Fibroblasts; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Induced Pluripotent Stem Cells; Injections, Intramuscular; Ischemia; Mice, Inbred C57BL; Muscle, Skeletal; Muscular Diseases; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Random Allocation; Reperfusion Injury; Signal Transduction | 2015 |
Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies.
Topics: Cell Differentiation; Endothelial Cells; Humans; Induced Pluripotent Stem Cells; Nitric Oxide; Obesity; Pluripotent Stem Cells; Pravastatin | 2019 |
Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice.
Topics: Adiponectin; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Eating; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Oxygen Consumption; Pravastatin; Random Allocation; Resistin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triglycerides | 2008 |
Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
Topics: Adult; Aged; Alcohol Drinking; Cholesterol; Combined Modality Therapy; Comorbidity; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Incidence; Japan; Lipoprotein(a); Male; Middle Aged; Obesity; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Smoking; Stroke | 2009 |
Obesity and hyperhomocysteinaemia after kidney transplantation.
Topics: Adult; Aged; Cohort Studies; Combined Modality Therapy; Diet Therapy; Drug Therapy, Combination; Female; Folic Acid; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Hyperhomocysteinemia; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Obesity; Postoperative Complications; Pravastatin; Probability; Prospective Studies; Risk Assessment; Treatment Outcome; Vitamin B 6 | 2003 |
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Topics: Body Mass Index; C-Reactive Protein; Cohort Studies; Comorbidity; Coronary Disease; Diabetes Mellitus; Follow-Up Studies; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Obesity; Pravastatin; Predictive Value of Tests; Risk Assessment; Scotland; Triglycerides | 2003 |
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Models, Biological; Models, Theoretical; Obesity; Pravastatin | 2006 |
[Statin therapy: cost-effectiveness and evaluation of evidence as criterium for improving expenditure within the National Health Program].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Italy; Middle Aged; National Health Programs; Obesity; Pravastatin; Thyroiditis, Autoimmune | 2006 |
Effect of pravastatin on the development of diabetes and adiponectin production.
Topics: Adipocytes; Adiponectin; Animals; Diabetes Mellitus; Disease Models, Animal; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Obesity; Pravastatin | 2008 |
Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferon Regulatory Factor-3; Interferon-beta; Interleukin-6; Macrophages; Male; Mice; Mice, Obese; Myeloid Differentiation Factor 88; Obesity; Pravastatin; Quinolines; Signal Transduction; Toll-Like Receptor 4 | 2008 |
[Treatment of hyperlipidemia in obese patients: monotherapy versus bi-therapy].
Topics: Adult; Bezafibrate; Cholesterol; Cholesterol, HDL; Drug Evaluation; Drug Therapy, Combination; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Pravastatin; Triglycerides | 1995 |
Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Heart; Insulin; Insulin Resistance; Linear Models; Male; Multivariate Analysis; Myocardium; Obesity; Pravastatin; Triglycerides | 1998 |